Magstim Academy Lecture Series – Rhythm and Acceleration – recent advances in TMS treatment for mood disorders. Mark George, MD, Nolan Williams, MD and Martijn Arns, PhD will present on their recently published and on-going TMS studies.
Magstim® TMS has launched the very first Transcranial Magnetic Stimulation navigation system specifically developed for the clinical market.
Magstim has received FDA clearance to include intermittent Theta Burst Stimulation (iTBS) as a treatment for Major Depressive Disorder with its Horizon® TMS Therapy systems.
How we treat depression in the future may be set to change as the NHS begins an unprecedented two year study using transcranial magnetic stimulation (TMS).
Magstim Group, Inc., the pioneer in trans-cranial magnetic stimulation and intraoperative nerve monitoring, today announced that it has appointed Lothar Krinke, Ph.D., as Chief Executive Officer effective immediately. Dr. Krinke will serve on the Board of Directors of Magstim. He will be responsible for Magstim and Technomed.